Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.

Castaman G, Borchiellini A, Santagostino E, Tagariello G, Serban M, Uscatescu M, Truica C, Albert F, Morfini M.

Haemophilia. 2019 Sep 11. doi: 10.1111/hae.13828. [Epub ahead of print] No abstract available.

PMID:
31509326
2.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results.

Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH MS, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J.

Blood. 2019 Aug 23. pii: blood.2019001542. doi: 10.1182/blood.2019001542. [Epub ahead of print]

PMID:
31444162
3.

Hemophilia A and B: molecular and clinical similarities and differences.

Castaman G, Matino D.

Haematologica. 2019 Sep;104(9):1702-1709. doi: 10.3324/haematol.2019.221093. Epub 2019 Aug 8. No abstract available.

4.

Risk of bleeding and thrombosis in inherited qualitative fibrinogen disorders.

Castaman G, Giacomelli SH, Biasoli C, Contino L, Radossi P.

Eur J Haematol. 2019 Jul 17. doi: 10.1111/ejh.13296. [Epub ahead of print]

PMID:
31314131
5.

The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study.

Tosetto A, Testa S, Palareti G, Paoletti O, Nichele I, Catalano F, Morandini R, Di Paolo M, Tala M, Esteban P, Cora' F, Mannino S, Maroni A, Sessa M, Castaman G.

Intern Emerg Med. 2019 Jul 15. doi: 10.1007/s11739-019-02148-7. [Epub ahead of print]

PMID:
31309520
6.

TNF-α/TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A.

Manetti M, Linari S, Romano E, Rosa I, Carulli C, Innocenti M, Matucci-Cerinic M, Ibba-Manneschi L, Castaman G, Melchiorre D.

J Clin Med. 2019 Jun 28;8(7). pii: E939. doi: 10.3390/jcm8070939.

7.

Pregnancy and delivery in women with von Willebrand disease.

Castaman G, James PD.

Eur J Haematol. 2019 Aug;103(2):73-79. doi: 10.1111/ejh.13250. Epub 2019 May 31. Review.

PMID:
31107984
8.

Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.

Lunghi B, Bernardi F, Martinelli N, Frusconi S, Branchini A, Linari S, Marchetti G, Castaman G, Morfini M.

J Thromb Haemost. 2019 Aug;17(8):1288-1296. doi: 10.1111/jth.14473. Epub 2019 May 29.

PMID:
31055871
9.

Current and emerging biologics for the treatment of hemophilia.

Castaman G, Linari S.

Expert Opin Biol Ther. 2019 Aug;19(8):801-810. doi: 10.1080/14712598.2019.1614163. Epub 2019 May 9.

PMID:
31039049
10.

Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B.

Gill JC, Roberts J, Li Y, Castaman G.

Haemophilia. 2019 May;25(3):e219-e222. doi: 10.1111/hae.13735. Epub 2019 Mar 13. No abstract available.

PMID:
30866086
11.

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB.

Blood Transfus. 2019 Feb 4:1-8. doi: 10.2450/2019.0183-18. [Epub ahead of print]

12.

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH.

Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K; subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders.

J Thromb Haemost. 2018 Dec;16(12):2530-2533. doi: 10.1111/jth.14315. Epub 2018 Nov 15. No abstract available.

PMID:
30430726
13.

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.

Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, Federici AB, Rossi E, Santoro R, Siragusa S; Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Hemostasis; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Haemostasis (see Appendix 1), De Stefano V, Falanga A, Tosetto A, Avvisati G, Carpenedo M, Federici AB, Marietta M, Napolitano M, Rossi E, Santoro C, Castaman G, Cerchiara E, Chistolini A, Contino L, Mazzucconi MG, Nichele I, Russo L, Santi R, Santoro RC, Siragusa S, Tagariello G.

Blood Transfus. 2019 May;17(3):171-180. doi: 10.2450/2018.0143-18. Epub 2018 Oct 24.

14.

XXV Congresso Nazionale della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET).

Ageno W, Falanga A, Castaman G.

Blood Transfus. 2018 Nov 7;16(Supplement no. 4):s415-s562. doi: 10.2450/2018.S4. [Epub ahead of print] No abstract available.

15.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.

J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.

16.

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls.

Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A.

Haemophilia. 2018 Sep;24(5):726-732. doi: 10.1111/hae.13595. Epub 2018 Aug 16.

PMID:
30112863
17.

Inhibitors in Hemophilia B.

Santoro C, Quintavalle G, Castaman G, Baldacci E, Ferretti A, Riccardi F, Tagliaferri A.

Semin Thromb Hemost. 2018 Sep;44(6):578-589. doi: 10.1055/s-0038-1660817. Epub 2018 Jun 20. Review.

PMID:
29925096
18.

The benefits of prophylaxis in patients with hemophilia B.

Castaman G.

Expert Rev Hematol. 2018 Aug;11(8):673-683. doi: 10.1080/17474086.2018.1489719. Epub 2018 Jul 18. Review.

PMID:
29909699
19.

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

Szederjesi A, Baronciani L, Budde U, Castaman G, Lawrie AS, Liu Y, Montgomery R, Peyvandi F, Schneppenheim R, Várkonyi A, Patzke J, Bodó I.

J Thromb Haemost. 2018 Jun 13. doi: 10.1111/jth.14206. [Epub ahead of print]

PMID:
29897666
20.

Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks.

Castaman G, Linari S.

Expert Rev Hematol. 2018 Jul;11(7):567-576. doi: 10.1080/17474086.2018.1486704. Epub 2018 Jun 19. Review.

PMID:
29886751
21.

von Willebrand factor regulation of blood vessel formation.

Randi AM, Smith KE, Castaman G.

Blood. 2018 Jul 12;132(2):132-140. doi: 10.1182/blood-2018-01-769018. Epub 2018 Jun 4. Review.

22.

Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE).

Coppola A, Franchini M, Castaman G, Santagostino E, Santoro C, Santoro RC, Morfini M, Di Minno G, Rocino A; AICE ad hoc Working Group.

Semin Thromb Hemost. 2018 Sep;44(6):551-560. doi: 10.1055/s-0038-1648230. Epub 2018 May 3. Review.

PMID:
29723892
23.

Management of thrombocytopenia in cancer.

Castaman G, Pieri L.

Thromb Res. 2018 Apr;164 Suppl 1:S89-S93. doi: 10.1016/j.thromres.2018.02.001. Review.

PMID:
29703490
24.

Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.

Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A.

Thromb Haemost. 2018 Mar;118(3):451-460. doi: 10.1055/s-0038-1624581. Epub 2018 Feb 15.

25.

Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown.

Abdi A, Linari S, Pieri L, Voorberg J, Fijnvandraat K, Castaman G.

Semin Thromb Hemost. 2018 Sep;44(6):568-577. doi: 10.1055/s-0037-1621717. Epub 2018 Feb 13. Review.

PMID:
29439277
26.

Hemophilia A: different phenotypes may be explained by multiple and variable effects of the causative mutation in the F8 gene.

Castaman G.

Haematologica. 2018 Feb;103(2):195-196. doi: 10.3324/haematol.2017.186353. No abstract available.

27.

Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.

Schinco P, Castaman G, Coppola A, Cultrera D, Ettorre C, Giuffrida AC, Marchesini E, Marino R, Milan M, Molinari C, Siboni SM, Zanon E, Federici AB.

Blood Transfus. 2018 Jul;16(4):371-381. doi: 10.2450/2017.0354-16. Epub 2017 May 26. Review.

28.

Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population.

Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Iorio A, Mannucci PM.

Haemophilia. 2018 Jan;24(1):e6-e10. doi: 10.1111/hae.13379. Epub 2017 Dec 22. No abstract available.

PMID:
29271531
29.

Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.

Castaman G, Linari S.

Expert Opin Drug Metab Toxicol. 2018 Feb;14(2):143-151. doi: 10.1080/17425255.2018.1420161. Epub 2017 Dec 27. Review.

PMID:
29257899
30.

Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.

Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, Tangelder M, Castaman G, Schwäble J, Bonig H, Seifried E, Cattaneo F, Meyer C, Leebeek FWG.

Blood. 2018 Mar 1;131(9):1022-1031. doi: 10.1182/blood-2017-09-804419. Epub 2017 Dec 15.

31.

Thrombin potential and traditional coagulation assay: are they useful in exploring recurrent pregnancy loss risk?

Romagnuolo I, Attanasio M, Cozzolino M, Paladino E, Castaman G, Coccia ME, Fatini C.

Blood Coagul Fibrinolysis. 2018 Mar;29(2):160-166. doi: 10.1097/MBC.0000000000000675.

PMID:
29135477
32.
33.

Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.

Castaman G, Linari S.

J Clin Med. 2017 Apr 10;6(4). pii: E45. doi: 10.3390/jcm6040045. Review.

34.

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.

Iorio A, Barbara AM, Makris M, Fischer K, Castaman G, Catarino C, Gilman E, Kavakli K, Lambert T, Lassila R, Lissitchkov T, Mauser-Bunschoten E, Mingot-Castellano ME, Ozdemir N, Pabinger I, Parra R, Pasi J, Peerlinck K, Rauch A, Roussel-Robert V, Serban M, Tagliaferri A, Windyga J, Zanon E.

Haemophilia. 2017 Mar;23(2):255-263. doi: 10.1111/hae.13167. Epub 2017 Feb 15.

35.

Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations.

Branchini A, Ferrarese M, Campioni M, Castaman G, Mari R, Bernardi F, Pinotti M.

Blood. 2017 Apr 20;129(16):2303-2307. doi: 10.1182/blood-2016-09-738641. Epub 2017 Feb 14.

36.

Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies.

Quon DV, Klamroth R, Kulkarni R, Shapiro AD, Baker RI, Castaman G, Kerlin BA, Tsao E, Allen G.

Haemophilia. 2017 Jan;23(1):e39-e42. doi: 10.1111/hae.13125. Epub 2016 Dec 11. No abstract available.

PMID:
27943467
37.

European retrospective study of real-life haemophilia treatment.

Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, Castaman G, Álvarez-Román MT, Parra Lopez R, Oldenburg J, Albert T, Scholz U, Holmström M, Schved JF, Trossaërt M, Hermans C, Boban A, Ludlam C, Lethagen S.

Haemophilia. 2017 Jan;23(1):105-114. doi: 10.1111/hae.13111. Epub 2016 Oct 20.

PMID:
27761962
38.

A contribution to the debate about the possible different clinical severity between hemophilia A and B.

Melchiorre D, Linari S, Matucci-Cerinic M, Castaman G.

Haematologica. 2016 Oct;101(10):e430. No abstract available.

40.

Clinical relevance of isolated prolongation of the activated partial thromboplastin time in a cohort of adults undergoing surgical procedures.

Tagariello G, Radossi P, Salviato R, Zardo M, De Valentin L, Basso M, Castaman G.

Blood Transfus. 2017 Oct;15(6):557-561. doi: 10.2450/2016.0047-16. Epub 2016 Jul 22.

41.

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.

Castaman G, Linari S.

Ther Clin Risk Manag. 2016 Jun 30;12:1029-37. doi: 10.2147/TCRM.S87543. eCollection 2016. Review.

42.

Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party.

Tagariello G, Castaman G, Falanga A, Santoro R, Napolitano M, Storti S, Veneri D, Basso M, Candiotto L, Tassinari C, Federici AB, De Stefano V; GIMEMA Haemostasis and Thrombosis working party.

Blood Transfus. 2016 Nov;14(6):521-526. doi: 10.2450/2016.0321-15. Epub 2016 Jun 24.

43.

Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality.

Castaman G, Federici AB.

Semin Thromb Hemost. 2016 Jul;42(5):478-82. doi: 10.1055/s-0036-1579638. Epub 2016 May 5. Review.

44.

Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.

Castaman G, Eckhardt C, van Velzen A, Linari S, Fijnvandraat K.

Semin Thromb Hemost. 2016 Jul;42(5):507-12. doi: 10.1055/s-0036-1571309. Epub 2016 May 5. Review.

PMID:
27148839
45.

Risk of thrombosis in cancer and the role of supportive care (transfusion, catheters, and growth factors).

Castaman G.

Thromb Res. 2016 Apr;140 Suppl 1:S89-92. doi: 10.1016/S0049-3848(16)30105-0. Review.

PMID:
27067986
46.

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, von Depka Prondzinski M, Altisent C, Castaman G, Yamamoto K, Álvarez-Roman MT, Voigt C, Blackman N, Jacobs I; PROLONG-9FP Investigators Study Group.

Blood. 2016 Apr 7;127(14):1761-9. doi: 10.1182/blood-2015-09-669234. Epub 2016 Jan 11.

47.

Ongoing developments in our understanding of haemophilia - perspectives on the therapeutic and immunogenic potential of Factor VIII (Il Ciocco - Barga (LU), 5-6 June 2015).

Castaman G, Farrugia A.

Blood Transfus. 2015 Dec 18:s527-s559. doi: 10.2450/2015.S4. [Epub ahead of print] No abstract available.

48.

Clinical manifestations and management of Gaucher disease.

Linari S, Castaman G.

Clin Cases Miner Bone Metab. 2015 May-Aug;12(2):157-64. doi: 10.11138/ccmbm/2015.12.2.157. Epub 2015 Oct 26. Review.

49.

Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres.

Franchini M, Di Perna C, Santoro C, Castaman G, Siboni SM, Zanon E, Linari S, Gresele P, Pasca S, Coppola A, Santoro R, Napolitano M, Ranalli P, Tagliaferri A; Italian Association of Haemophilia Centres.

Semin Thromb Hemost. 2016 Feb;42(1):36-41. doi: 10.1055/s-0035-1564844. Epub 2015 Nov 23.

PMID:
26595151
50.

Hematological manifestations and complications of Gaucher disease.

Linari S, Castaman G.

Expert Rev Hematol. 2016 Jan;9(1):51-8. doi: 10.1586/17474086.2016.1112732. Epub 2015 Nov 13. Review.

PMID:
26565753

Supplemental Content

Loading ...
Support Center